EpiVax’s follows the 2019-nCoV epidemic

EpiVax’s follows the 2019-nCoV epidemic

2019-nCOV (Coronavirus):  What to know, and what to expect? Unless you have been in a media blackout these past two weeks, you are well aware of the latest public health threat: 2019-nCoV. This new strain of coronavirus is currently linked to over forty...
EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...